Browse the corpus

Dalteparin sodium is a low molecular weight heparin (LMWH) medication used to manage venous thromboembolism (VTE), deep vein thrombosis (DVT), and ischemic complications of unstable angina and non-Q-wave myocardial infarction. The medication is derived from unfractionated heparin to form LMWH and is commonly administered as a subcutaneous injection. Symptoms of overdose necessitate urgent medical attention, with protamine sulfate as an antidote. Routine complete blood counts and stool occult blood tests are recommended during treatment with dalteparin, and patients with renal insufficiency require additional monitoring. Concomitant use of medications that affect coagulation may pose similar risks as other heparins. This activity provides comprehensive information about the mechanism of action, adverse event profile, and other key factors. The dosing strategies, pharmacokinetics, monitoring, drug-drug interactions, and contraindications are pertinent for interprofessional team members treating conditions when the agent is indicated. In particular, clinicians from emergency medicine, critical care, or hospitalists may be better equipped to manage a prevalent set of thromboembolic conditions. Objectives: Assess the patient’s condition and history to determine the indication for dalteparin therapy. Differentiate dalteparin from other forms of heparin regarding dosing, administration, and pharmacokinetics. Select the appropriate dosage and administration route for dalteparin based on clinical context. Collaborate within the interprofessional team to educate, treat, and monitor patients in hypercoagulable states using dalteparin to improve patient outcomes. Access free multiple choice questions on this topic.

Dalteparin causes less hepatic and renal deposition than UFH. Overdosage and toxicity symptoms of dalteparin include unusual bleeding, blood in urine, black, tarry stools, easy bruising, red blood in stools, and vomit that is bloody or looks like coffee grounds.  The FDA states that overdosage may lead to hemorrhagic complications. This can be managed by slow IV injection of protamine sulfate with 1 mg of protamine sulfate for every 100 anti-Xa IU dalteparin. Carcinogenic Effects According to the results of long-term animal studies, dalteparin sodium has unknown potential to cause cancer. However, the medication is non-mutagenic in multiple tests, including the in vitro Ames Test, mouse lymphoma cell forward mutation test, human lymphocyte chromosomal aberration test, and the in vivo mouse micronucleus test. Furthermore, subcutaneous doses of dalteparin sodium up to 1200 IU/kg did not affect male and female fertility or reproductive performance. Teratogenic Effects No evidence of impaired fertility or harm to fetuses was found in reproduction studies with dalteparin sodium in pregnant rats and rabbits at IV doses up to 2400 and 4800 IU/kg, respectively. However, no adequate studies have been conducted on pregnant women. Use during pregnancy should be limited to cases where the medication is necessary.

Dalteparin is an anticoagulant administered subcutaneously to prevent and treat VTE. Patients undergoing treatment should maintain regular appointments with their clinicians to monitor blood counts, transaminases, and therapeutic drug levels, ensuring the desired anticoagulant effects. Symptoms of overdose, such as unusual bleeding, blood in urine, black or tarry stools, easy bruising, red blood in stools, or bloody vomit resembling coffee grounds, warrant immediate medical attention. In cases of overdosage, an IV injection of protamine sulfate can be administered. Admitted patients should have a care team, including clinicians, pharmacists, and lab technicians, collaborating to prevent subtherapeutic effects or overdosage.